TABLE 6

Potential therapeutic application of EP3 agonists

AgonistRouteDoseSpeciesExperimental ModelIndicationReference
MB 28767Intravenous2 pmol · kg−1 · min−1PigOcclusion/reperfusionCardiac infarctionHohlfeld et al., 2000
MB 28767Intracisternal1 fg–30 ng per animalMouseNaloxone-induced withdrawal jumpingOpiate withdrawal syndromeNakagawa et al., 1995
ONO-AE-248Subcutaneous10 μg/kgMouseOvalbumin induced asthmaAsthmaKunikata et al., 2005
TEI-3356Intravenous1 μg · kg−1 · h−1RatOcclusion/reperfusionCardiac infarctionZacharowski et al., 1999
  • TEI-3356, 5-(-7-hydroxy-6-(4-hydroxy-4-methyl-1-octenyl)bicyclo(3.3.0)oct-2-en-3-yl)pentanoic acid.